133 related articles for article (PubMed ID: 23126234)
1. Emerging cell-cycle inhibitors for pancreatic cancer therapy.
Bayraktar S; Rocha Lima CM
Expert Opin Emerg Drugs; 2012 Dec; 17(4):571-82. PubMed ID: 23126234
[TBL] [Abstract][Full Text] [Related]
2. Advanced or metastatic pancreatic cancer: molecular targeted therapies.
Bayraktar S; Rocha-Lima CM
Mt Sinai J Med; 2010; 77(6):606-19. PubMed ID: 21105124
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
Matera R; Saif MW
Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
[TBL] [Abstract][Full Text] [Related]
5. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
[TBL] [Abstract][Full Text] [Related]
6. Promises and drawbacks of targeting cell cycle kinases in cancer.
Pentimalli F; Giordano A
Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
9. A review of kinases implicated in pancreatic cancer.
Giroux V; Dagorn JC; Iovanna JL
Pancreatology; 2009; 9(6):738-54. PubMed ID: 20090395
[TBL] [Abstract][Full Text] [Related]
10. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
11. Emerging cell cycle inhibitors for acute myeloid leukemia.
Abou Zahr A; Borthakur G
Expert Opin Emerg Drugs; 2017 Jun; 22(2):137-148. PubMed ID: 28506135
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
14. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer.
Fendrich V; Lauth M
Expert Opin Ther Targets; 2014 Nov; 18(11):1277-83. PubMed ID: 25078025
[TBL] [Abstract][Full Text] [Related]
15. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle inhibitors for the treatment of NSCLC.
Shcherba M; Liang Y; Fernandes D; Perez-Soler R; Cheng H
Expert Opin Pharmacother; 2014 May; 15(7):991-1004. PubMed ID: 24666387
[TBL] [Abstract][Full Text] [Related]
17. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
Stone A; Sutherland RL; Musgrove EA
Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with kinase inhibitors in aggressive endocrine tumors.
Marotta V; Franzese MD; Del Prete M; Chiofalo MG; Ramundo V; Esposito R; Marciello F; Pezzullo L; Carratù A; Vitale M; Colao A; Faggiano A
Expert Opin Pharmacother; 2013 Jun; 14(9):1187-203. PubMed ID: 23675883
[TBL] [Abstract][Full Text] [Related]
20. Update on Aurora Kinase Targeted Therapeutics in Oncology.
Green MR; Woolery JE; Mahadevan D
Expert Opin Drug Discov; 2011 Mar; 6(3):291-307. PubMed ID: 21556291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
